Purpose: Insurers often commission psychiatric experts to evaluate the eligibility of workers with mental disorders for disability benefits, by estimating their residual work capacity (RWC). We investigated the validity of a standardized, computer-based battery of established diagnostic instruments, for evaluating the personality, cognition, performance, symptom burden, and symptom validity of claimants.
Methods: One hundred and fifty-three claimants for benefits were assessed by the assembled test battery, which was applied in addition to a conventional clinical work disability evaluation.
Results: A principal component analysis of the test and questionnaire battery data revealed six factors (, , , , and ). Claimants with low, medium, and high RWC exclusively varied in the factor . Importantly, this factor also showed a strong association to psychiatric ratings of capacity limitations in psychosocial functioning.
Conclusions: The findings demonstrate that the used test battery allows a substantiation of RWC estimates and of psychiatric ratings by objective and standardized data. If routinely incorporated in work disability evaluations, the test battery could increase their transparency for all stakeholders (insurers, claimants, medical experts, expert case-coordinators, and legal practitioners) and would open new avenues for research in the field of insurance medicine.Implications for rehabilitationThe residual work capacity (RWC) estimation by medical experts is internationally good practice, but plagued by a relatively low interrater agreement.The current study shows that psychiatric RWC estimates and capacity limitation ratings can be substantiated by data from objective, standardized psychometric instruments.Systematically using such instruments might help to improve the poor interrater agreement for RWC estimates in work disability evaluations.Such data could also be used for adopting vocational trainings and return-to-work programs to the individual needs of workers with mental health problems.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/09638288.2022.2151655 | DOI Listing |
Alzheimers Dement
December 2024
University of Saint Joseph, West Hartford, CT, USA.
Background: Many individuals with health problems and/or disabilities are largely dependent on the help of an informal caregiver, most often a family member with whom they live (CDC Report, 2018). A recent report by the Alzheimer's Association (2023) found that, compared with caregivers of people without dementia, twice as many caregivers of those with dementia have reported significant emotional, financial, and physical difficulties. Despite the important role that caregivers have in our society, research on potential factors that may buffer the negative impacts of caregiving has been lacking.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Newcastle University, Newcastle, Tyne and Wear, United Kingdom.
Background: Approximately 944,000 people are living with dementia in the UK (∼0.8% of the population). The World Health Organisation consider dementia a public health priority.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Hull, Hull, United Kingdom.
Background: Dementia rarely travels alone. People with dementia (PwD) often have multiple other physical diagnoses (multimorbidity) and experience poor quality, fragmented care. Over two thirds of carers of PwD are spouses, over half of which are 85 years old or above.
View Article and Find Full Text PDFCrit Care Resusc
December 2024
Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
Objective: Extracorporeal membrane oxygenation (ECMO) is a high-risk procedure with significant morbidity and mortality and there is an uncertain volume-outcome relationship, especially regarding long-term functional outcomes. The aim of this study was to examine the association between ECMO centre volume and long-term death and disability outcomes.
Design Setting And Participants: This is a registry-embedded observational cohort study.
Int J MS Care
January 2025
Novartis Pharmaceuticals UK Ltd, London, United Kingdom.
Background: The PANORAMA survey aimed to assess current treatment practice for individuals with new diagnoses of relapsing-remitting multiple sclerosis (RRMS) in the United Kingdom and to explore variations in treatment approaches with an emphasis on escalation vs early high-efficacy treatment (HET) and treatment goals.
Methods: Health care professionals (HCPs) from the UK treating patients with RRMS took part in interviews facilitated by a structured questionnaire. Data were analyzed descriptively using quantitative or qualitative methods, as appropriate.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!